Thomas L. Richie, MD, Phd
Dr. Richie is Director of Vaccine Discovery and Clinical Development at SIGHTM and has over 24 years experience directing infectious disease and clinical trials research. He concurrently serves as Chief Medical Officer at Sanaria Inc., leading the development and testing of Sanaria’s clinical products. Tom’s clinical and regulatory team is sponsoring or co-sponsoring 18 clinical trials of Sanaria’s malaria vaccines in the US, Europe and Africa during 2014-16. This is done through collaborations with the 35 institutions from 14 countries that comprise the International PfSPZ Consortium.
Prior to joining SIGHTM and Sanaria in January 2014, Tom was an active duty Navy Captain serving as the Research Coordinator for the U.S. Military Malaria Vaccine Program, Naval Medical Research Center (NMRC) / Walter Reed Army Institute of Research (WRAIR), in Silver Spring, Maryland, and also serving as the Director, Navy Malaria Program. He led a diverse translational research enterprise to develop a malaria vaccine, bridging from genomics and bioinformatics to antigen discovery, vaccine concept development, and preclinical and clinical testing. In earlier assignments in the Navy, Tom served as the Director of the Malaria Program, U.S. Naval Medical Research Unit #2 in Jakarta, Indonesia (1992-98) and Founding Director, NMRC Clinical Trials Center (1998-2004).
ALexander D. Hoffman, JD
Mr. Hoffman is the Executive Director of SIGHTM, Chief Legal Officer at Sanaria Inc. and General Counsel at Protein Potential, LLC. At each he is responsible for corporate legal matters, business development, insurance, and information technology. He has negotiated the hundreds of contracts, research agreements, collaborations, and other types of partnerships that have taken the PfSPZ Vaccine from a concept to a reality and continues to ensure that these partnerships and collaborations remain strong. He sits on the Board of the Akumaning-Brewu Foundation.
David Smith, Phd
Dr. Smith is a collaborator from the University of Washington who uses a wide variety of quantitative tools to investigate how infectious diseases persist in populations through transmission, the associated burden on human health, the effects of interventions put in place to reduce transmission and the burden of disease, and the economics of those decisions. Dr. Smith's current research agenda is dominated by the dynamics and control of malaria, but also addresses the evolution of antimalarial drug and antibiotic resistance and the dynamics of cholera, rabies, flu, and various bacterial pathogens.